Paul Schimmel - 10 May 2023 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
Director
Signature
/s/ Nancy E. Denyes, Attorney-in-Fact
Issuer symbol
ATYR
Transactions as of
10 May 2023
Net transactions value
+$450,000
Form type
4
Filing time
11 May 2023, 09:00:16 UTC
Previous filing
28 Apr 2023
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common Stock Purchase $450,000 +200,000 +177% $2.25 313,023 10 May 2023 See Footnote F1, F2
holding LIFE Common Stock 8,890 10 May 2023 Direct
holding LIFE Common Stock 679,143 10 May 2023 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents weighted average price for the shares. The shares were purchased ranging from $2.245 to $2.25 per share under the issuer's "at-the-market" offering program implemented pursuant to the issuer's Open Market Sale Agreement with Jefferies LLC. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F2 These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.
F3 These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.